SYRS: Syros Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.14
Enterprise Value ($M) 3.14
Book Value ($M) 0.00
Book Value / Share 0.00
Price / Book n/a
NCAV ($M) 0.00
NCAV / Share 0.00
Price / NCAV n/a

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -0.73
Return on Equity (ROE) -6.50

Liquidity (mrq)
Quick Ratio n/a
Current Ratio n/a

Balance Sheet (mrq) ($M)
Current Assets 0.00
Assets 0.00
Liabilities 0.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
03-27 13D/A Samsara BioCapital, L.P. 2.60 -71.89
02-14 13G/A Avidity Partners Management LP 7.60 -28.33
02-14 13G/A Point72 Asset Management, L.P. 0.00 -99.97
02-14 13G/A Deep Track Capital, LP
02-12 13G/A Adage Capital Partners Gp, L.l.c. 1.98 -79.73
11-14 13G/A Blue Owl Capital Holdings LP 1.92 -65.45
11-14 13G/A Bain Capital Life Sciences Fund II, L.P. 9.99 0.01
11-12 13G/A Invus Global Management, LLC 9.90 2.31

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-07-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)

Similar Companies
STMH – Stem Holdings, Inc. SWGHF – Sawai Group Holdings Co., Ltd.
SYBE – Sybleu Inc. TBEV – High Performance Beverages Company
TBIO – Telesis Bio, Inc.


Financial data and stock pages provided by
Fintel.io